The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Scaffold-free Three-dimensional Graft From Autologous Adipose-derived Stem Cells for Large Bone Defect Reconstruction: Clinical Proof of Concept
Open accessAbstract
Long bone nonunion in the context of congenital pseudarthrosis or carcinologic resection (with intercalary bone allograft implantation) is one of the most challenging pathologies in pediatric orthopedics. Autologous cancellous bone remains the gold standard in this context of long bone nonunion reconstruction, but with several clinical limitations. We then assessed the feasibility and safety of human autologous scaffold-free osteogenic 3-dimensional (3D) graft (derived from autologous adipose-derived stem cells [ASCs]) to cure a bone nonunion in extreme clinical and pathophysiological conditions. Human ASCs (obtained from subcutaneous adipose tissue of 6 patients and expanded up to passage 4) were incubated in osteogenic media and supplemented with demineralized bone matrix to obtain the scaffold-free 3D osteogenic structure as confirmed in vitro by histomorphometry for osteogenesis and mineralization. The 3D "bone-like" structure was finally transplanted for 3 patients with bone tumor and 3 patients with bone pseudarthrosis (2 congenital, 1 acquired) to assess the clinical feasibility, safety, and efficacy. Although minor clones with structural aberrations (aneuploidies, such as tri or tetraploidies or clonal trisomy 7 in 6%-20% of cells) were detected in the undifferentiated ASCs at passage 4, the osteogenic differentiation significantly reduced these clonal anomalies. The final osteogenic product was stable, did not rupture with forceps manipulation, did not induce donor site morbidity, and was easily implanted directly into the bone defect. No acute (<3 mo) side effects, such as impaired wound healing, pain, inflammatory reaction, and infection, or long-term side effects, such as tumor development, were associated with the graft up to 4 years after transplantation. We report for the first time that autologous ASC can be fully differentiated into a 3D osteogenic-like implant without any scaffold. We demonstrated that this engineered tissue can safely promote osteogenesis in extreme conditions of bone nonunions with minor donor site morbidity and no oncological side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![FIGURE 2 Genetic stability of ASCs in bone tumor context. Karyotype and FISH (FLI1-EWSR1 double fusion probe) analyses for the native tumor (A, arrow: t[11;22] [q24;q12]) and undifferentiated (B) and differentiated (C, arrow: t[14;15] [q32;q11.2]) ASC at P4 for patient 3: the FLI1-EWSR1 double fusion signals detected on the native tumour cells (A) were not detected in the ASCs at P4 (B, C), but minority tetrasomies of both probes by FISH suggesting tetraploidy were found for undifferentiated ASCs (B). Initial trisomy 8 was not detected, but minority tetraploidy (detected by the tetrasomies of both probes by FISH) was found after osteogenic differentiation (C) in comparison to the native tumor tissue. ASCs = adipose-derived stem cells, FISH = fluorescence in situ hybridization, P4 = passage 4.](https://figures.cochat.ai/paper-figures/a91abb33c0cd42dba6e13be3e72c651e/scaffold-free-three-dimensional-graft-from-autologous-adipose-derived-stem-cells-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In total, six patients with bone sarcoma were treated (three osteosarcomas, two Ewing sarcomas and one with chondrosarcoma).”
From Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice (2019) · cites this paper as [179]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Abnormal tissue formation was reported in one patient who had osteosarcoma recurrence, likely related to insufficient surgical margins after primary tumour resection.”
From Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice (2019) · cites this paper as [179]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“In both studies, it was observed over time that all patients experienced favorable general clinical outcomes characterized by successful fracture healing and effective filling of bone defects [89,107,108].”
From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [108]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The final osteogenic product was stable and did not induce acute or long-term donor site morbidity up to 4 years after transplantation.”
From Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice (2019) · cites this paper as [179]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, there was no incidence of ASCs promoting a pro-tumor TME.”
From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [108]
Experimental — accuracy not yet measured
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based Therapies
Zuk, P. A., Zhu, M., Mizuno, H., Huang, J., Futrell, J. W., Katz, A. J., Benhaim, P., Lorenz, H. P., & Hedrick, M. H. (2001) · Tissue Engineering · doi:10.1089/107632701300062859 · Cited by 7,956
Human Adipose Tissue Is a Source of Multipotent Stem Cells
Zuk, P. A., Zhu, M., Ashjian, P., De Ugarte, D. A., Huang, J. I., Mizuno, H., Alfonso, Z. C., Fraser, J. K., Benhaim, P., & Hedrick, M. H. (2002) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-02-0105 · Cited by 6,664
Bone: Formation by Autoinduction
Urist, M. R. (1965) · Science · doi:10.1126/science.150.3698.893 · Cited by 5,546
Liao, J., Wei, Q., Zou, Y., Fan, J., Song, D., Cui, J., Zhang, W., Zhu, Y., Ma, C., Hu, X., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000471945 · Cited by 2,742
Adipose-derived stem cells for regenerative medicine
Gimble, J. M., Katz, A. J., & Bunnell, B. A. (2007) · Circulation Research · doi:10.1161/01.res.0000265074.83288.09 · Cited by 2,332
Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells
Rehman, J., Traktuev, D., Li, J., Merfeld-Clauss, S., Temm-Grove, C. J., Bovenkerk, J. E., Pell, C. L., Johnstone, B. H., Considine, R. V., & March, K. L. (2004) · Circulation · doi:10.1161/01.cir.0000121425.42966.f1 · Cited by 2,269
Bone regeneration: current concepts and future directions
Dimitriou, R., Jones, E., McGonagle, D., & Giannoudis, P. V. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-66 · Cited by 2,003 · cited 1×
“To date, no synthetic or biological scaffolds fulfil all these criteria since they can be influenced by the surrounding microenvironments or cause immunological problems.(25,26) Several scaffold-free systems have been investigated, but creating sufficient thickness to fill a critical size bone defect is difficult.”
BackgroundOsteogenesis in transplants of bone marrow cells
Friedenstein, A. J., Piatetzky-Shapiro, I. I., & Petrakova, K. V. (1966) · Development · doi:10.1242/dev.16.3.381 · Cited by 1,671
Fat tissue: an underappreciated source of stem cells for biotechnology
Fraser, J. K., Wulur, I., Alfonso, Z., & Hedrick, M. H. (2006) · Trends in Biotechnology · doi:10.1016/j.tibtech.2006.01.010 · Cited by 1,058
Autogenous Iliac Crest Bone Graft: Complications and Functional Assessment
Goulet, J. A., Senunas, L. E., DeSilva, G. L., & Greenfield, M. L. V. H. (1997) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-199706000-00011 · Cited by 909 · cited 1×
“The current gold standard for bone nonunion remains autologous cancellous bone graft from iliac crest (in most cases and in a small bone defect) containing bone marrow mesenchymal stem cells (MSCs), but available quantities are limited and the harvesting procedure is burdened by comorbidities.(7,8) The use of osteoind…”
Background
Cited by
Stem Cells in Bone Regeneration
Walmsley, G. G., Ransom, R. C., Zielins, E. R., Leavitt, T., Flacco, J. S., Hu, M. S., Lee, A. S., Longaker, M. T., & Wan, D. C. (2016) · Stem Cell Reviews and Reports · doi:10.1007/s12015-016-9665-5 · Cited by 170
“utilized a combination of osteogenically differentiated ASCs and DBM to create three-dimensional autografts for treatment of bony nonunion in patients with pseudoarthritis or post-tumor resections [30].”
MethodImpact of Age on Human Adipose Stem Cells for Bone Tissue Engineering
Dufrane, D. (2017) · Cell Transplantation · doi:10.1177/0963689717721203 · Cited by 148
Self-citationMesenchymal Stem Cell Therapy for Bone Regeneration
Jin, Y., & Lee, J. H. (2018) · Clinics in Orthopedic Surgery · doi:10.4055/cios.2018.10.3.271 · Cited by 146
Gentile, P., Calabrese, C., Angelis, B. D., Pizzicannella, J., Kothari, A. S., & Garcovich, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215471 · Cited by 143
Zhou, Z., Sun, T., Chen, F., Zuo, D., Wang, H., Hua, Y., Cai, Z., & Tan, J. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.12.031 · Cited by 121
Metadata
- Authors
- Dufrane, D., Docquier, P.-L., Delloye, C., Poirel, H. A., André, W., & Aouassar, N.
- Affiliations
- Cliniques Universitaires Saint-Luc (BE)
- Corresponding author
- Dufrane, Denis
- Venue
- Medicine
- Published
- 2015-12
- Volume
- 94
- Issue
- 50
- Pages
- e2220
- ISSN
- 0025-7974 (ISSN-L)
- PMC
- PMC5058905
- OpenAlex
- W2314226316
- Cited by
- 66
- References
- 41
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 6 · 2023: 6 · 2022: 4 · 2021: 4 · 2020: 9 · 2019: 9 · 2018: 6 · 2017: 5 · 2016: 6
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Medicine (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › Bone Tissue Engineering Materials
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone fractures and treatments
- Keywords
- adipose-derived stem cells, osteogenic differentiation, long bone nonunion, congenital pseudarthrosis, bone tumor resection, demineralized bone matrix, donor site morbidity, bone defect repair, pediatric orthopedics
- MeSH terms
- Adolescent, Bone Neoplasms, Cell Differentiation, Child, Feasibility Studies, Female, Humans, Male, Pseudarthrosis, Osteosarcoma, Stem Cells, Adipocytes, Tissue Engineering, Tissue Scaffolds
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Scaffold-free Three-dimensional Graft From Autologous Adipose-derived Stem Cells for Large Bone Defect Reconstruction: Clinical Proof of Concept. https://app.cochat.ai/papers/10.1097/md.0000000000002220
- The paper
- Dufrane, D., Docquier, P.-L., Delloye, C., Poirel, H. A., André, W., & Aouassar, N. (2015). Scaffold-free Three-dimensional Graft From Autologous Adipose-derived Stem Cells for Large Bone Defect Reconstruction: Clinical Proof of Concept. Medicine. https://doi.org/10.1097/md.0000000000002220
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.